Article
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Breast cancer research and treatment - 1 Jan 2012
Park In Hae, Ro Jungsil, Park Sohee, Lim Hyeong-Seok, Lee Keun Seok, Kang Han Sung, Jung So-Youn, Lee Seeyeon
Abstract excerpt
Active metabolites of tamoxifen are formed mainly by the action of cytochrome P450 2D6 (CYP2D6). Since there are controversies regarding associations between CYP2D6 polymorphisms and outcomes among women with early breast cancer (EBC) treated with tamoxifen, the present evaluation of links with clinical outcomes was conducted. We analyzed a total of 716 patients treated with tamoxifen for hormone receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.